Butyric Acid

Butyric Acid

SCHEMBL5571749

CCCC(=O)[O-].CCCC(=O)[O-].[Be+2]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 3/20 0.93
HDAC3 O15379 3/20 0.93
HDAC1 Q13547 3/20 0.93
HDAC2 Q92769 3/20 0.93
HDAC8 Q9BY41 3/20 0.93
CA1 P00915 3/20 0.60
CES2 O00748 2/20 0.59
CES1 P23141 2/20 0.59
TSHR P16473 1/20 0.53
NFKB1 P19838 1/20 0.48
GPR84 Q9NQS5 1/20 0.46
FABP3 P05413 2/20 0.44
CA2 P00918 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL107100 0.93
Butyric Acid SCHEMBL1330878 0.93
Butyric Acid SCHEMBL9800297 0.93 FFAR3 (0.93) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL2587931 0.93 FFAR3 (0.93) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL11441641 0.93 FFAR3 (0.93) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL10908702 0.93 FFAR3 (0.93) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL11814057 0.93 FFAR3 (0.93) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL11419652 0.93 FFAR3 (0.93) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL4292004 0.93 FFAR3 (1.00) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL1176373 0.93 FFAR3 (0.93) FFAR3HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070074717-A1 Heating recycling system for regenerating the absorptive materials AKOS ADVANCED TECHNOLOGY LIMITED (HK) 2007-04-05 US claimed
US-6652770-B2 For prevention of the increase of temperature in heat sensitive devices through the absorption of heat during heat generating conditions HAYES CLAUDE Q C (US) 2003-11-25 US claimed
US-6261475-B1 THERMOSENSITIVE ELEMENTS HAYES CLAUDE Q C (US) 2001-07-17 US claimed
US-11192875-B2 Processes for preparing antiviral compounds GILEAD PHARMASSET LLC (US) 2021-12-07 US disclosed
US-20200392100-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2020-12-17 US disclosed
US-10584109-B2 Processes for preparing antiviral compounds Gillead Pharmasset LLC (US) 2020-03-10 US disclosed
US-20190263771-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2019-08-29 US disclosed
US-20180179175-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC 2018-06-28 US disclosed
US-9890134-B2 Processes for preparing antiviral compounds GILEAD PHARMASSET LLC (US) 2018-02-13 US disclosed
US-20170283390-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2017-10-05 US disclosed
US-9670187-B2 Processes for preparing antiviral compounds GILEAD PHARMASSET LLC (US) 2017-06-06 US disclosed
EP-3154984-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2017-04-19 EP disclosed
US-20150361073-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2015-12-17 US disclosed
WO-2015191437-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC (US) 2015-12-17 WO disclosed
US-20070074717-A1 Heating recycling system for regenerating the absorptive materials AKOS ADVANCED TECHNOLOGY LIMITED (HK) 2007-04-05 US disclosed
US-6261475-B1 THERMOSENSITIVE ELEMENTS HAYES CLAUDE Q C (US) 2001-07-17 US disclosed
EP-0034918-B1 SHAPE SELECTIVE REACTIONS WITH BERYLLIUM-MODIFIED ZEOLITE CATALYSTS MOBIL OIL CORPORATION (US) 1984-05-16 EP disclosed
EP-0034918-A1 Shape selective reactions with beryllium-modified zeolite catalysts MOBIL OIL CORPORATION (US) 1981-09-02 EP disclosed
US-4260843-A ALKYLATION MOBIL OIL CORPORATION (US) 1981-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10584109-B2 Processes for preparing antiviral compounds MAVS, EIF2AK2, SAMHD1 FFAR3 4718/4885HDAC3 4383/4885HDAC1 3545/4885
US-11192875-B2 Processes for preparing antiviral compounds MAVS, EIF2AK2, SAMHD1 FFAR3 4718/4885HDAC3 4383/4885HDAC1 3545/4885
US-20170283390-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 FFAR3 4718/4885HDAC3 4383/4885HDAC1 3545/4885
US-20150361073-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 FFAR3 4718/4885HDAC3 4383/4885HDAC1 3545/4885
US-20180179175-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 FFAR3 4718/4885HDAC3 4383/4885HDAC1 3545/4885
US-20200392100-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 FFAR3 4718/4885HDAC3 4383/4885HDAC1 3545/4885
US-20190263771-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 FFAR3 4718/4885HDAC3 4383/4885HDAC1 3545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.